Pfizer's haemophilia B gene therapy meets phase 3 primary endpoint - - Pharmaphorum

Retrieved on: 2023-01-03 10:24:43

Tags for this article:

Click the tags to see associated articles and topics

Pfizer's haemophilia B gene therapy meets phase 3 primary endpoint - - Pharmaphorum. View article details on hiswai:

Excerpt

Pfizer announced positive top-line results from phase 3 study evaluating fidanacogene elaparvovec, a gene therapy for haemophilia B.

Article found on: pharmaphorum.com